FTSE MIB
33.988,75 +359,54 (+1,07%) Dow Jones
38.675,68 +449,98 (+1,18%) Nasdaq
16.156,33 +315,33 (+1,99%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
78,96 +0,85 (+1,09%) Bitcoin EUR
59.613,95 +347,46 (+0,59%)
Precipio, Inc. (PRPO)
| Chiusura precedente | 5,89 |
| Aperto | 5,75 |
| Denaro | 4,98 x 100 |
| Lettera | 6,84 x 100 |
| Min-Max giorno | 5,75 - 6,00 |
| Intervallo di 52 settimane | 4,75 - 14,80 |
| Volume | |
| Media Volume | 4.271 |
| Capitalizzazione | 8,523M |
| Beta (5 anni mensile) | 1,25 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,51 |
| Prossima data utili | 15 mag 2024 - 20 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 19,00 |
GlobeNewswirePrecipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
Company anticipates current cash levels sufficient to reach breakevenNEW HAVEN, Conn., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that the combination of revenue growth and cost cutting initiatives has reduced Cash Burn From Operations (CBFO) by 59% compared to the same quarter last year, from approximately $2.5M/quarter to $1M/quarter. Management has set a target of reaching financial independence with its current cash reserve
- GlobeNewswire
Precipio Continues to Sign New HemeScreen™ Customers
New customer orders received in Q3 exceed $1M annualized revenueNEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M. In a recent announcement, the company announced that the product revenue necessary to reach cash flow breakeven has been reduced to $6M annualized run rate, or $1.5M/quarter. As of today, Precipio forecasts
- GlobeNewswire
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
Higher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6MNEW HAVEN, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduced the revenue required from the products division to reach breakeven from $8M to $6M annually, or $1.5M per quarter, 25% below previous estimates. This m
